- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00605527
Understanding the Role of Genes and Biomarkers in the Inflammation and Blood Clotting Process in Children With Acute Lung Injury (PALI)
Targeted Genomic Analysis of Coagulation Pathways in Acute Lung Injury
Aperçu de l'étude
Statut
Les conditions
Description détaillée
ALI/ARDS is a life-threatening condition that involves inflammation of the lungs and fluid accumulation in the air sacs, which leads to low blood oxygen levels and respiratory failure. Common causes include pneumonia, sepsis, and lung trauma. Symptoms, including breathing difficulty, low blood pressure, and organ failure, usually develop within 24 to 48 hours of the original injury or illness. Most patients require immediate care in an intensive care unit, and the main form of treatment is mechanical ventilation, which delivers oxygen and a continuous level of pressure to the damaged lungs. Although progress has been made in understanding how ALI/ARDS develops, it is still unknown why recovery outcomes differ among people. Differences in the genetic basis of protein C and fibrinolysis pathways, which both play a role in preventing blood clots, may be a factor in determining the severity of and recovery from ALI. The purpose of this study is to analyze plasma and DNA from children with ALI/ARDS to identify biomarkers and genetic variations that may be related to clinical outcomes.
This study will enroll children who are hospitalized with ALI/ARDS. Participants' medical records will be reviewed to gather information about symptoms, physical exam findings, mechanical ventilator settings, and laboratory test results. A blood collection will occur on Days 1 and 3. Study researchers will analyze plasma biomarkers and use high throughput DNA sequencing technology to analyze participants' DNA.
Type d'étude
Inscription (Réel)
Contacts et emplacements
Lieux d'étude
-
-
California
-
Fresno, California, États-Unis, 93710
- Children's Hospital Central California
-
Los Angeles, California, États-Unis, 90027
- Children's Hospital Los Angeles
-
Oakland, California, États-Unis, 94609
- Children's Hospital & Research Center of Oakland
-
San Francisco, California, États-Unis, 94143
- University of California, San Francisco
-
-
Wisconsin
-
Madison, Wisconsin, États-Unis, 53792
- American Family Children's Hospital
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
La description
Inclusion Criteria:
- Hospitalized and requiring supplemental oxygen
- Meets the American-European consensus definition of ALI/ARDS, defined as partial pressure of oxygen in arterial blood/fraction of inspired oxygen (PaO2/FiO2) ratio of less than 300 mm Hg, bilateral opacities on a chest radiograph, and either a pulmonary wedge pressure of less than 18 mm Hg or the absence of clinical evidence of left atrial hypertension
- Acute pulmonary parenchymal disease (i.e., onset of bilateral infiltrates on chest radiograph within 48 hours of screening)
- PaO2/FiO2 less than or equal to 300 mm Hg, regardless of the mean airway pressure
- At least one arterial blood gas confirming partial pressure of oxygen/fraction of inspired oxygen (PO2/FiO2) ratio less than 300 mm Hg or Fi02/Sao2 on pulse oximetry of less than 320
Exclusion Criteria:
- Clinical signs of left ventricular failure, pulmonary capillary wedge pressure greater than 18 mm Hg, or evidence, such as echocardiography, suggesting a cardiac basis for the pulmonary edema
- Presence of right-to-left intracardiac shunt
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: Cohorte
- Perspectives temporelles: Éventuel
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Number of ventilator-free days
Délai: Measured during participant's hospital stay
|
Measured during participant's hospital stay
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Mortality and organ dysfunction
Délai: Measured during participant's hospital stay
|
Measured during participant's hospital stay
|
Collaborateurs et enquêteurs
Parrainer
Collaborateurs
Les enquêteurs
- Chercheur principal: Anil Sapru, MD, MAS, University of California, San Francisco
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
- Maladies des voies respiratoires
- Troubles respiratoires
- Maladies pulmonaires
- Blessures et Blessures
- Nourrisson, nouveau-né, maladies
- Nourrisson, Prématuré, Maladies
- Blessures thoraciques
- Syndrome de détresse respiratoire
- Syndrome de détresse respiratoire, nouveau-né
- Lésion pulmonaire aiguë
- Lésion pulmonaire
Autres numéros d'identification d'étude
- 545
- K23HL085526 (Subvention/contrat des NIH des États-Unis)
- K23HL085526-01A1 (Subvention/contrat des NIH des États-Unis)
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .